Enterome Bioscience has appointed Christophe Bonny as CSO. He will be responsible for developing and advancing Enterome's R&D strategy, focusing on the identification of novel targets derived from the microbiome and the development of molecules secreted by the gut microbiome. Bonny joins Enterome from Bicycle Therapeutics, where he served as CSO. He also previously worked at Switzerland-based Xiagen where he served as CSO and president. Prior to Xiagen, Bonny served as head of research of the medical genetics unit at the University Hospital of Lausanne in Switzerland.